Integrating Ci-Ca therapy in your clinical practice.
Many critically ill patients in intensive care units (ICUs) are suffering from multi-organ failure and they depend on reliable application of organ support therapies.13
The multiFiltratePRO offers a wide range of therapeutic applications, mostly in intensive care, such as:
* Legal manufacturer of multiECCO2Ris EUROSETS S.r.l., Italy. Ģý Deutschland GmbH is a distributor of multiECCO2Rin selected countries.
Aiming to further enhance the quality of patient care and healthcare operations, multiFiltratePRO enables built-in HL7 connectivity to your PDMS (Patient Data Management System). Efficient and secure device interoperability with the multiFiltratePRO is designed to enable data-driven decision making, streamline workflows and reduce transcription errors.14
HL7 connectivity flyer
PDF, 300 KB1Weidhase L et al. Plos One 2019; 14:e0215823
2Eichhorn T et al. Blood Purif 2017; 44:260-266
3Weidhase et al. Crit Care 2020; 24:644
4Hafner S et al. J Intensive Care 2015; 3:35
5Bianchi NA et al. Blood Purif 2020; 49:567-575
6Kalb R et al. Ther Apher Dial 2013; 17:202-212
7Zarbock A et al. JAMA 2020;324:1629-1639
8Morgera et al. Crit Care Med 2009;37:2018-2024
9Slowinski T et al. Crit Care 2015; 19:349
10Houllé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35-41
11Link A et al. Crit Care 2012; 16:R97
12Huguet M et al. Int J Artif Organs 2017; 40:676-682
13ICNARC. Case Mix Programme Summary Statistics 2019-20, www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics, accessed April 2021
14Fieler VK, Jaglowski T, Richards K. Eliminating errors in vital signs documentation. Comput Inform Nurs. 2013;31(9):422-427.